Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02159209 · ClinicalTrials.gov registry record
The Drug Induced Renal Injury Consortium
A clinical trial of Acute Kidney Injury and Kidney Disease, sponsored by Ravindra Mehta.
- Completed
- Registry status
- 634
- Enrollment target
- 18
- Study locations
NCT02159209: Completed study of Acute Kidney Injury and Kidney Disease, sponsored by Ravindra Mehta.
NCT02159209 is a study of Acute Kidney Injury and Kidney Disease that has completed, run by Ravindra Mehta. The registered enrollment target is 634 participants, below the 2,322-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (73% lower). The trial reports 18 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02159209, a study of Acute Kidney Injury and Kidney Disease, has completed, sponsored by Ravindra Mehta.
- COMPLETED
- Registry status
- 634 participants
- Enrollment target
- 18
- Study locations
Study Summary
Some medications are known to cause kidney damage because the person is allergic to the medication while others cause direct damage to the kidney because they are toxic at certain concentrations. Risk factors for developing kidney damage have been identified for some medications but not for all. Patients who are exposed to these important medications and develop problems with their kidneys may have some genetic risk. The purpose of this study is to determine the genetic risk factors for drug induced kidney injury. A better understanding of the role of genetics for the development of kidney injury from medications will allow us to better select medications, improve effectiveness of treatment and minimize harm.
Primary Outcome
Blood Draw (20 cc) and urine collection (80cc)
Conditions Studied
Study Locations (18)
Other
- Universidad del Valle, Cochabamba - Cochabamba
- Universidad de Los Andes - Santiago
- Postgraduate Institute of Research, Chandigarh - Chandigarh
- Royal Free Hospital - London
- Guy's & St Thomas's Hospital - London
- University of Nottingham - Nottingham
California
- University of California, San Diego - San Diego
- Rady Children's Hospital - San Diego
New York
- St. Peter's Hospital - Albany
- Jacobi Medical Center - New York
Alabama
- University of Alabama, Birmingham - Birmingham
Colorado
- University of Colorado - Aurora
Michigan
- University of Michigan - Ann Arbor
Ohio
- Cincinnati Children's Hospital - Cincinnati
Quebec
- Hopital Sacre Coeur & Universite de Montreal - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 634 participants |
| Start Date | 2013-02 |
| Est. Completion | 2015-12 |
What the finished NCT02159209 record still lists
NCT02159209 is an observational study that tracks outcomes without assigning an intervention. The registered 634 participants enrollment target is mid-sized for trials with a published cap, below the 2,322-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (73% lower).
The record links to 5 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 0 interventions.
NCT02159209 lists 18 locations in 11 states (Other, California, New York).
Frequently Asked Questions
What is clinical trial NCT02159209 about?
NCT02159209 is a clinical study titled "The Drug Induced Renal Injury Consortium". Some medications are known to cause kidney damage because the person is allergic to the medication while others cause direct damage to the kidney because they are toxic at certain concentrations. Risk factors for developing kidney damage have been identified for some medications but not for all. Pat...
What is the current status of trial NCT02159209?
This trial is currently completed. The enrollment target is 634 participants. The study started on 2013-02. Estimated completion is 2015-12.
What conditions does trial NCT02159209 study?
This clinical trial studies the following conditions: Acute Kidney Injury, Kidney Disease, Kidney Failure, Acute Kidney Failure, Adverse Drug Reaction.
Who is sponsoring clinical trial NCT02159209?
This trial is sponsored by Ravindra Mehta, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02159209 being conducted?
This trial has 18 study locations across Alabama, California, Colorado, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02159209's enrollment target sits among peer trials
634 18th of 74 higher than 57 of 74 other Acute Kidney Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Kidney Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ultra-Low Contrast Angiography in AKI
RECRUITING · Phase 3
-
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
RECRUITING
-
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
RECRUITING
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage
RECRUITING · Phase 1
-
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573027 · 634 participants · NA
Heart Disease of the Small Arteries in Women and Men
- NCT04108156 · 634 participants · Phase 3
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
- NCT07237295 · 634 participants · NA
CommunityRx-Kidney Health
- NCT03478826 · 635 participants
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia